CELL THERAPY MANUFACTURING MARKET ANALYSIS

Cellular therapy is the transplantation of human cells to replace or repair damaged tissue or cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. Hematopoietic (blood-forming) stem cells (HSC), skeletal muscle stem cells, mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells are a few of the cells that could be used.

Global cell therapy manufacturing market is estimated to be valued at US$ 3,755.4 million in 2022 and is expected to exhibit a CAGR of 15.2% during the forecast period (2022-2030).

Figure 1. Global Cell Therapy Manufacturing Market Share (%), by Application, 2022

To learn more about this report, request a free sample copy

Global Cell Therapy Manufacturing Market- Drivers

Manufacturers are involved in developing and launching various types of technologies for cell therapy manufacturing, which is expected to propel the growth of global cell therapy manufacturing market. For instance, in July 2022, INVETECH, a global company offering solutions, systems, and services to cell and gene therapy, announced the launch of new korus technology for autologous cell therapy production. Korus is a closed system for the production of autologous cell therapy. Providing elutriation and cell washing using gentle counterflow centrifugation to remove contaminants and produce a purified population of target cells.

Manufacturers of cell therapy product are in receiving regulatory approvals to enhance their cell therapy manufacturing process, which in turn is expected to drive the global cell therapy manufacturing market growth. For instance, in May 2022, the U.S. Food and Drug Administration announced that it had approved Novartis’s chimeric antigen receptor (CAR) T-cell therapy Kymriah, for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Figure 2. Global Cell Therapy Manufacturing Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Global Cell Therapy Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of medical devices, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Players operating in the global cell therapy manufacturing market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials due to irregularities in transportation facility. Furthermore, distributors are experiencing irregular demand for products from the retailers due to rising incidence of COVID -19.

However, there has been a slight positive impact on market as cell therapies are under research for the treatment of COVID-19. For instance, According to an research published on February 20, 2022, by the Springer Nature, mesenchymal cells (MSCs) are currently been studied as one of the treatment methods to treat COVID-19 disease. Researchers use immunosuppressive drugs (Tocilizumab) to alleviate COVID-19 symptoms in patients, these cells, due to their mechanism of action, can significantly improve critical conditions. Use of MSCs has shown positive effects for the treatment of COVID-19 as these cells can modulate the immune system.

Global Cell Therapy Manufacturing Market: Key Developments

In May 2020, WuXi Advanced Therapies, a contract development and manufacturing organization (CDMO) of WuXi AppTec., a Pharmaceutical company, announced that it had expanded its service capabilities to offer a fully integrated, closedprocess CAR-T cell therapy platform. This new platform will shorten the timeframe for developing, manufacturing, and delivering cell and gene therapies while providing better predictability.

Global Cell Therapy Manufacturing Market: Restraint

High cost of cell therapies is one of the biggest challenges, with financial implications for patients, payers, and providers, which is expected to hamper the market growth over the forecast period. For instance, in May 2022, chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) received the U.S. FDA approval for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) and it costs around US$ 475,000 for a single infusion. This has resulted in limited adoption of such therapies, thereby hampering growth of the market. Moreover, in April 2022, Yescarta, a cell therapy was approved by the U.S. FDA for the treatment of certain B-cell lymphomas. The listed price for axicabtagene ciloleucel (Yescarta) in the U.S. is US$ 373,000.

Global Cell Therapy Manufacturing Market- Key Players

Major players operating in the global cell therapy manufacturing market include Wuxi AppTec, Inc, Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.